Pricing and reimbursement and Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer market access, Reports, Avastin, Alimta, Iressa, Tarceva

PRMA Insights: the Roadmap to Pricing and Reimbursement Success in Non-Small Cell Lung Cancer 2nd edition

Use this 350+ page strategic resource to:

Design a roadmap for your NSCLC product to achieve successful global market access
Ensure your strategic plan reflects current and future market access realities
Understand the pricing and reimbursement implications for NSCLC products in the US, UK, France, Germany, Spain, Italy, and Japan
Develop and refine pricing and reimbursement strategies
Design your clinical development program to ensure relevant health economic and patient-reported outcome endpoints are captured
Build forecast models that reflect market access realities
Inform candidate selection and R&D portfolio prioritization
Assess in-licensing opportunities and identify market access levers to negotiate favorable deal terms
Develop an evidence-based value proposition in order to maximize deal value for your out-licensed product

To find out more about this publication and how it can help you optimize your product development download the brochure:

Fill in the fields below and press submit. A member of our team
will respond shortly.